Tonix Pharmaceuticals Holding Corp. · NASDAQ:TNXP
Tonix Pharmaceuticals — Investor Presentation (March 2021)
64 slides from Tonix Pharmaceuticals's investor presentation, Mar 17, 2021
Slide 1: Investor Presentation
© 2021 Tonix Pharmaceuticals Holding Corp. 1 March 2021 Version P0282 3 - 17 - 2021 (Doc 0802) Investor Presentation NASDAQ:TNXP
Slide 2: Cautionary Note on Forward-Looking Statements
© 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are “forward - looking statements” as defined by the Private Securities Litigat
Slide 3: Who We Are – Mission And Purpose
© 2021 Tonix Pharmaceuticals Holding Corp. 3 Tonix Pharmaceuticals Who We Are – Mission And Purpose Clinical - stage biopharmaceutical company that invents and develops medicines to help patients manage the central nervous system (CNS) and immunology diseases. “Advancing science to improve patient c
Slide 4: Our Pipeline – CNS Portfolio
© 2021 Tonix Pharmaceuticals Holding Corp. 4 Our Pipeline – CNS Portfolio CANDIDATES INDICATION STATUS CNS Portfolio TNX - 102 SL 1 Fibromyalgia (FM) - Lead Program Mid - Phase 3 – ongoing PTSD Phase 3 ready Agitation in Alzheimer’s Phase 2 ready Alcohol Use Disorder Phase 2 ready TNX - 1300 2 Cocai
Slide 5: Our Pipeline – Immunology & Biodefense Portfolio
© 2021 Tonix Pharmaceuticals Holding Corp. 5 Our Pipeline – Immunology & Biodefense Portfolio CANDIDATES INDICATION STATUS Immunology Portfolio TNX - 1800 Covid - 19 vaccine – Prioritized Program 1 Preclinical TNX - 2100 SARS - CoV - 2 skin test for T cell immunity 2 Pre - IND TNX - 2300 Covid - 19
Slide 6: TNX-102 SL: New Potential Treatment for the Management of Fibromyalgia
© 2021 Tonix Pharmaceuticals Holding Corp. 6 TNX - 102 - SL 1 : New Potential Treatment for the Management of Fibromyalgia 1 TNX - 102 SL (cyclobenzaprine HCl sublingual tablets) is an investigational new drug and has not been approved for any indication.
Slide 7: Background on Fibromyalgia
© 2021 Tonix Pharmaceuticals Holding Corp. 7 TNX - 102 SL FM Lead Program Background on Fibromyalgia Fibromyalgia (FM): A chronic condition Core symptoms: • widespread pain • sleep disturbance • fatigue • cognitive symptoms. Significant disabilities (impaired daily function). Course of disease can l
Slide 8: Challenges with Current Pharmacotherapy
© 2021 Tonix Pharmaceuticals Holding Corp. 8 Challenges with Current Pharmacotherapy Limitations of Current Therapies Fewer than half of those treated for fibromyalgia receive relief from the three FDA - approved drugs 1 • Lack of overall response leading to discontinuation or augmentation • Lack of
Slide 9: Fibromyalgia Unmet Need and Ideal Treatment Profile
© 2021 Tonix Pharmaceuticals Holding Corp. 9 Fibromyalgia Unmet Need and Ideal Treatment Profile Unmet Medical Need: Current treatment patterns indicate that new, more effective, and better - tolerated treatments are necessary for management of FM 1 Source: 1. Yang, et al, 2016 Ideal Treatment Profi
Slide 10: TNX-102 SL: Engineered to Treat FM
© 2021 Tonix Pharmaceuticals Holding Corp. 10 TNX - 102 SL: Engineered to Treat FM This unique formulation of cyclobenzaprine has been designed to optimize delivery and absorption, while minimizing the potential residual effects of oral formulations of cyclobenzaprine. Innovative and proprietary Pro
Slide 11: Results from Completed Positive Phase 3 RELIEF Study
© 2021 Tonix Pharmaceuticals Holding Corp. 11 TNX - 102 SL 5.6 mg: Results from Completed Positive Phase 3 RELIEF Study Completed Positive Trial in FM: • Topline results announced in December 2020 • 503 participants randomized across 39 sites in U.S. • 95% of participants were women Topline Efficacy
Slide 12: Phase 3 F304/RELIEF Study: Design
© 2021 Tonix Pharmaceuticals Holding Corp. 12 Positive Phase 3 F304/RELIEF Study: Design Primary e ndpoint (Week 14) : • Daily diary pain severity score change (TNX - 102 SL 5.6 mg vs. placebo) from baseline in the weekly average as measured by the numerical rating scale (NRS), using mixed model rep
Slide 13: F304/RELIEF Topline Data: Primary Efficacy Endpoint
© 2021 Tonix Pharmaceuticals Holding Corp. 13 F304/RELIEF Study Topline Data: Statistical Significance Achieved on Pre - specified Primary Efficacy Endpoint (p=0.01) ◊ ◊ 2 TNX - 102 SL is in clinical stage of development and not approved for any indication Primary Outcome Measure at Week 14 Placebo
Slide 14: F304/RELIEF Primary Efficacy Endpoint Results (continued)
© 2021 Tonix Pharmaceuticals Holding Corp. 14 F304/RELIEF Study: Primary Efficacy Endpoint Results (continued) -2.2 -2 -1.8 -1.6 -1.4 -1.2 -1 -0.8 -0.6 -0.4 -0.2 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 LS Mean Change from Baseline (SE) in NRS Pain Score Study Week RELIEF Study Mean Change from Baseline
Slide 15: F304/RELIEF Key Secondary Efficacy Endpoints
© 2021 Tonix Pharmaceuticals Holding Corp. 15 F304/RELIEF Study: Key Secondary Efficacy Endpoints ◊ ◊ *TNX - 102 SL is in clinical stage of development and not approved for any indication Outcome Measure at Week 14 Intent - to - Treat Analysis 1 P - value Non - Specific Patient Global Impression of
Slide 16: F304/RELIEF Continuous Responder Analysis Graph
© 2021 Tonix Pharmaceuticals Holding Corp. 16 P e r c e n t o f S u b j e c t s 0 10 20 30 40 50 60 70 80 90 100 Percentage Redution in Pain >=0% >=10% >=20% >=30% >=40% >=50% >=60% >=70% >=80% >=90% =100% Placebo TNX-102 SL Proportion of Subjects in Arm Cut - Off Points for Percentage Pain Responde
Slide 17: Adverse Events in F304/RELIEF Study
© 2021 Tonix Pharmaceuticals Holding Corp. 17 Adverse Events* (AEs) in F304/ RELIEF Study TNX - 102 SL (N=248) Placebo (N=255) Total (N=503) Administration Site Reactions N % N % N % Tongue/mouth numbness 43 17.3 2 0.8 45 8.9 Tongue/mouth pain/discomfort 29 11.7 5 2.0 34 6.8 Taste impairment 16 6.5
Slide 18: Safety and Tolerability in F304/RELIEF Study
© 2021 Tonix Pharmaceuticals Holding Corp. 18 Safety and Tolerability in F304/RELIEF Study • No new safety signals in RELIEF at TNX - 102 SL 5.6 mg dose • 82.3% in active arm and 83.5% in placebo arm completed the study • 8.9% in active arm and 3.9% in placebo arm discontinued due to adverse events
Slide 19: Phase 3 F306/RALLY Study – Enrollment Ongoing
© 2021 Tonix Pharmaceuticals Holding Corp. 19 TNX - 102 SL 5.6 mg for Fibromyalgia: 2 nd Phase 3 F306/RALLY Study – Enrollment Ongoing Primary e ndpoint (Week 14) : • Daily diary pain severity score change (TNX - 102 SL 5.6 mg vs. placebo) from baseline in the weekly average as measured by the numer
Slide 20: Approved Fibromyalgia Pharmacotherapies
© 2021 Tonix Pharmaceuticals Holding Corp. 20 Approved Fibromyalgia Pharmacotherapies Pfizer • Drug: Lyrica® or pregabalin (U.S. patent expired in 2018) • Approved: 2004 • Mechanism: modulates nerve impulses involved in the transmission of pain through selective binding to the alpha2 - delta protein
Slide 21: Other Fibromyalgia Pharmacotherapies in Development in the U.S.
© 2021 Tonix Pharmaceuticals Holding Corp. 21 Other Fibromyalgia Pharmacotherapies in Development in the U.S. Axsome Therapeutics - AXS - 14 • Drug: esreboxetine • Mechanism: Selective norepinephrine reuptake inhibitor • Developmental Stage: At least mid - Phase 3 (Phase 2 and Phase 3 trial positive
Slide 22: TNX-102 SL Intellectual Property – U.S. Protection expected until 2035
© 2021 Tonix Pharmaceuticals Holding Corp. 22 TNX - 102 SL Intellectual Property – U.S. Protection expected until 2035 • United States Patent and Trademark Office (USPTO) issued United States Patent No. 9636408 in May 2017, Patent No. 9956188 in May 2018, Patent No. 10117936 in November 2018, and Pa
Slide 23: Opportunities to Expand TNX-102 SL to Other Indications
© 2021 Tonix Pharmaceuticals Holding Corp. 23 Opportunities to Expand TNX - 102 SL to Other Indications Growing recognition that there are many disorders where sleep disturbances may have a role in the pathophysiology (cardiovascular, metabolic, neurologic) • Sleep quality plays a homeostatic role i
Slide 24: TNX-1800, TNX-2300: COVID Vaccine Candidates and TNX-2100
© 2021 Tonix Pharmaceuticals Holding Corp. 24 TNX - 1800 1 , TNX - 2300 1 : COVID - 19 Vaccine Candidates and TNX - 2100 1 : Diagnostic Product Candidate to Test for SARS - CoV - 2 T Cell Immunity 1 TNX - 1800, TNX - 2300 and TNX - 2100 are in the pre - IND stage of development and have not been app
Slide 25: TNX-1800: a COVID Vaccine Candidate
© 2021 Tonix Pharmaceuticals Holding Corp. 25 TNX - 1800 1 : a COVID - 19 Vaccine Candidate • Utilizes Tonix’s proprietary horsepox virus as a vector • Encodes a protein from SARS - CoV - 2, the cause of COVID - 19 • Developed in collaboration with University of Alberta, Canada • Animal testing with
Slide 26: Concerns With Current COVID Vaccines with EUA
© 2021 Tonix Pharmaceuticals Holding Corp. 26 Concerns With Current COVID - 19 Vaccines with Emergency Use Authorization (EUA) • Durability of protection • Are vaccinated people protected one year later? • Durable protection is associated with T cell response • Protection against death/ventilator su
Slide 27: Warp-Speed COVID Vaccines: Live Virus Vaccines Take Longer to Develop
© 2021 Tonix Pharmaceuticals Holding Corp. 27 Warp - Speed COVID - 19 Vaccines: Live Virus Vaccines Take Longer to Develop • mRNA • Moderna (mRNA - 1273, LNP 1 - encapsulated CoV - 2 Spike [“Spike”] mRNA) EUA 2 • Pfizer & BioNTech ( LNP - encapsulated Spike mRNA ) EUA • Subunit • Sanofi/GSK (recombi
Slide 28: COVID Vaccine Landscape
© 2021 Tonix Pharmaceuticals Holding Corp. 28 COVID - 19 Vaccine Landscape • We expect more than one vaccine will be approved by FDA • Different vaccines for different individuals • More than 150 vaccines in development • Diversity of approaches is important since protective immunity is not yet unde
Slide 29: Live, Attenuated Virus Vaccines for Other Infectious Diseases
© 2021 Tonix Pharmaceuticals Holding Corp. 29 Live, Attenuated Virus Vaccines for Other Infectious Diseases 1 • Long term, durable immunity • Expected to stimulate T cells and provide years to decades of protection • Single administration, scalable manufacturing • Low dose is amplified by replicatio
Slide 30: TNX-1800: Engineered for Long-term Immunity
© 2021 Tonix Pharmaceuticals Holding Corp. 30 TNX - 1800 1 : Engineered for Long - term Immunity Based on “vaccinia” vaccine developed more than 200 years ago by Dr. Edward Jenner to prevent smallpox • TNX - 1800 has 99.7% colinear identity with circa 1860 smallpox vaccine 2 • Eradicated smallpox (o
Slide 31: TNX-1800 Vaccination of Non-Human Primates Elicited Neutralizing Antibodies
© 2021 Tonix Pharmaceuticals Holding Corp. 31 TNX - 1800 Vaccination of Non - Human Primates Elicited Anti - SARS - CoV - 2 Neutralizing Antibodies and Skin Reaction or “Take” in All Eight Animals STUDY DESIGN : Compares TNX - 1800 (modified horsepox virus encoding CoV - 2 spike protein) to TNX -
Slide 32: TNX-1800 Vaccination and SARS-CoV-2 Challenge of Non-Human Primates
© 2021 Tonix Pharmaceuticals Holding Corp. 32 TNX - 1800 Vaccination and SARS - CoV - 2 Challenge of Non - Human Primates Findings and Conclusions TOLERABILITY : TNX - 1800 and TNX - 801 were well tolerated at both doses. CHALLENGE WITH SARS - COV - 2: 41 days after vaccination, the TNX - 1800 v
Slide 33: Why Use a Horsepox Platform for a Vaccine?
© 2021 Tonix Pharmaceuticals Holding Corp. 33 Why Use a Horsepox Platform for a Vaccine? Horsepox can be engineered to express foreign genes • Lack of persistence or genomic integration in the host • Strong immunogenicity as a vaccine • Readily manufacture at scale • Live, attenuated vaccine – direc
Slide 34: TNX-1800 is Based on a Horsepox Virus Vector
© 2021 Tonix Pharmaceuticals Holding Corp. 34 TNX - 1800 is Based on a Horsepox Virus (HPXV) Vector Designed to Express SARS - CoV - 2 S Protein *TNX - 1800 is at the pre - IND stage of development Horsepox sHPXV ~200,000 Bp TNX - 1800 * rHPXV/SARS - CoV - 2S ~200,000 Bp Homologous Recombination
Slide 35: Vaccinia Induces a Skin Reaction Called “Take”
© 2021 Tonix Pharmaceuticals Holding Corp. 35 Vaccinia Induces a Skin Reaction Called “Take” – Described by Dr. Edward Jenner 1. Fulginiti VA, et al. Clin Infect Dis. 2003;37(2):241 - 250. 2. Liu L, et al. Nature Med. 2010;16(2):224 - 228. 3. Centers for Disease Control and Prevention. Accessed Apri
Slide 36: Unique Challenges of SARS-CoV-2
© 2021 Tonix Pharmaceuticals Holding Corp. 36 Unique Challenges of SARS - CoV - 2 SARS Rate of death 1,2 Deaths 2 Rate of infectivity 1 Incubation time 2 Asymptomatic 3 0.4 2 - 7 days ~13% ~10% SARS - CoV - 2 Rate of death 1,4 Deaths (as of Mar 2021) 5 Rate of infectivity 1,4 Incubation time 2,4 Asy
Slide 37: Infection of Type II Pneumocytes Can Lead to Lethal Respiratory Illness
© 2021 Tonix Pharmaceuticals Holding Corp. 37 Infection of Type II Pneumocytes Can Lead to Lethal Respiratory Illness Capillary Type II pneumocytes Inhalation Exhalation Type II pneumocytes in the alveoli secrete pulmonary surfactants that are necessary for effective gas exchange. 2 SARS - CoV - 2 I
Slide 38: SARS-CoV-2 Hijacks the Respiratory System to Spread Contagious Virus
© 2021 Tonix Pharmaceuticals Holding Corp. 38 SARS - CoV - 2 Hijacks the Respiratory System to Spread Contagious Virus Respiratory epithelium Capillary Airway Resting CD8 T cell Endothelial cell Exhalation spreads virus • Virus factories release virions by continuous budding • Breathing, speaking or
Slide 39: CoV-Specific T Cells Kill the Virus Factories
© 2021 Tonix Pharmaceuticals Holding Corp. 39 CoV - 2 Specific T Cells Kill the Virus Factories • Natural immunity or vaccine protection has the potential to decrease forward transmission • T cells specifically kill virally infected cells Bar - On YM, et al. eLife . 2020;9:e57309 . Respiratory epith
Slide 40: Contrasting T cell and Antibody Immunity
© 2021 Tonix Pharmaceuticals Holding Corp. 40 Contrasting T cell and Antibody Immunity • T cell immunity • Durable or long - lived (many years) • Recognize fragments of pathogens on the surfaces of infected cells • Cannot recognize pathogens directly • Potential to clear viral infections (by killing
Slide 41: TNX-1800: Potential Development and Uses
© 2021 Tonix Pharmaceuticals Holding Corp. 41 TNX - 1800: Potential Development and Uses • Potential to protect against CoV - 2 Variants • T cell epitopes are short stretches of peptides (~8 - 14 aa fragments) that so far seem to be conserved between variants • Clinical trials will test potential pr
Slide 42: TNX-2300 and SARS-CoV-2 Vaccine Platform: Bovine Parainfluenza Virus
© 2021 Tonix Pharmaceuticals Holding Corp. 42 TNX - 2300, 2 nd SARS - CoV - 2 Vaccine Platform: Bovine Parainfluenza (BPI) Virus Collaboration with Kansas State University to develop a vaccine candidate for the prevention of COVID - 19 • Utilizes a novel live attenuated vaccine vector platform and t
Slide 43: TNX-2100: Potential Skin Test to Measure SARS-CoV-2 Exposure
© 2021 Tonix Pharmaceuticals Holding Corp. 43 TNX - 2100 1 : Potential Skin Test to Measure SARS - CoV - 2 Exposure and T Cell Immunity TNX - 2100 (SARS - CoV - 2 epitope peptide mixtures for intradermal administration) • Based on mixtures of synthetic peptides for intradermal administration • Desig
Slide 44: TNX-2100: Potential Uses and Development Plans
© 2021 Tonix Pharmaceuticals Holding Corp. 44 TNX - 2100: Potential Uses and Development Plans TNX - 2100 has the potential to serve as: • a biomarker for cellular immunity and protective immunity • a method to stratify participants in COVID - 19 vaccine trials by immune status • an endpoint in COVI
Slide 45: TNX-1300: New Potential Treatment for Cocaine Intoxication
© 2021 Tonix Pharmaceuticals Holding Corp. 45 TNX - 1300 1 : New Potential Treatment for Cocaine Intoxication 1 TNX - 1300 is an investigational new biologic and has not been approved for any indication.
Slide 46: TNX-1300 for the Treatment of Cocaine Intoxication
© 2021 Tonix Pharmaceuticals Holding Corp. 46 TNX - 1300* for the Treatment of Cocaine Intoxication Recombinant protein that degrades cocaine in the bloodstream 1 • Double - mutant cocaine esterase ( CocE ) • CocE was identified in a bacterium ( Rhodococcus ) that use cocaine as its sole source of c
Slide 47: TNX-1300 Is a Fast-acting Cocaine Antidote
© 2021 Tonix Pharmaceuticals Holding Corp. 47 TNX - 1300 (Cocaine Esterase or CocE ) Is a Fast - acting Cocaine Antidote CocE Rhodococcus bacteria living in the roots of the coca plant use CocE to metabolize cocaine 1 CocE cleaves chemical bonds in cocaine and disintegrates it 800 times faster than
Slide 48: TNX-1300 Development Plan
© 2021 Tonix Pharmaceuticals Holding Corp. 48 TNX - 1300 Development Plan • Targeting to initiate a Phase 2 open - label, randomized pilot study of TNX - 1300 in the second quarter of 2021 • Emergency department (ED) setting with patients coming in for treatment of cocaine and/or polysubstance intox
Slide 49: TNX-1900 and TNX-2900: Intranasal Potentiated Oxytocin
© 2021 Tonix Pharmaceuticals Holding Corp. 49 TNX - 1900 1 : Intranasal Potentiated Oxytocin for Migraine and Craniofacial Pain and TNX - 2900 1 : Intranasal Potentiated Oxytocin for Prader - Willi Syndrome 1 TNX - 1900 and TNX - 2900 are in the pre - IND stage of development.
Slide 50: TNX-1900 for Migraine and Craniofacial Pain – Overview
© 2021 Tonix Pharmaceuticals Holding Corp. 50 TNX - 1900 (Intranasal Potentiated Oxytocin) for the Treatment of Migraine and Craniofacial Pain – Overview Novel intranasal ( i.n. ) oxytocin (OT) formulation being developed as a prophylactic treatment for chronic migraine • Based on a propriety formul
Slide 51: TNX-1900 for the Treatment of Migraine – Prevalence
© 2021 Tonix Pharmaceuticals Holding Corp. 51 TNX - 1900 for the Treatment of Migraine – Prevalence One billion individuals worldwide suffer from migraines (~14% of population) 1 Migraine is the second leading cause of years lived with disability 1 In U.S., the estimated cost of all migraine headach
Slide 52: TNX-1900 for Migraine – Mechanism of Action
© 2021 Tonix Pharmaceuticals Holding Corp. 52 TNX - 1900 for the Treatment of Migraine – Mechanism of Action Preclinical research showed that nasally applied TNX - 1900 selectively inhibits the activity of trigeminal pain - sensing nerve cells and blocks the release of CGRP • TNX - 1900 is believed
Slide 53: TNX-1900 Mechanism of Action (continued)
TNX - 1900 for the Treatment of Migraine – Mechanism of Action (continued) HEAD PAIN PATIENT USES TNX - 1900 TARGETED DELIVERY Permeates nasal mucosa Transported to trigeminal system and brain Proprietary Nasal to Brain Delivery CGRP: NEUROTRANSMITTER THAT HAS BEEN VALIDATED AS KEY MIGRAINE TARGET T
Slide 54: TNX-1900: Mechanism of Action (continued)
TNX - 1900: Mechanism of Action (continued) In animal models, intranasal oxytocin concentrates in the trigeminal system I nhibits trigeminal neuronal firing, and decreases CGRP (and PACP) release onto meningeal vasculature and within the brainstem - Believed to have effects on: - Neurogenic inflamma
Slide 55: TNX-1900 for Migraine – Development Status
© 2021 Tonix Pharmaceuticals Holding Corp. 55 TNX - 1900 for the Treatment of Migraine – Development Status In June 2020, Tonix acquired a proprietary formulation of nasal oxytocin solution for intranasal delivery from Trigemina Also acquired migraine and pain treatment technologies of Trigemina , I
Slide 56: TNX-2900 for Prader-Willi Syndrome – Overview
© 2021 Tonix Pharmaceuticals Holding Corp. 56 TNX - 2900 for the Treatment of Prader - Willi Syndrome – Overview TNX - 2900 is also based on Tonix’s patented intranasal potentiated oxytocin formulation and expands on this work Prader - Willi syndrome is the most common genetic cause of life - threat
Slide 57: TNX-1500: Monoclonal Antibody directed against CD40-Ligand
© 2021 Tonix Pharmaceuticals Holding Corp. 57 TNX - 1500 1 : Monoclonal Antibody directed against CD40 - Ligand for Organ Transplant Rejection and Autoimmune Conditions 1 TNX - 1500 is in the pre - IND stage of development.
Slide 58: TNX-1500, a New CD40 Ligand Antibody, for Allograft Rejection
© 2021 Tonix Pharmaceuticals Holding Corp. 58 TNX 1500, a New CD40 Ligand (CD40L) Antibody, for the Prevention of Allograft Rejection The CD40 - CD40L pathway is a pivotal immune system modulator and is a well - established and very promising treatment target to more safely prevent allograft rejecti
Slide 59: Pipeline Summary – by Select Therapeutic Areas
© 2021 Tonix Pharmaceuticals Holding Corp. 59 Pipeline 1 Summary – by Select Therapeutic Areas Pain Psychiatry Addiction Medicine • TNX - 102 SL (sublingual cyclobenzaprine) for fibromyalgia Phase 3/RELIEF Phase 3/RALLY • TNX - 102 SL (sublingual cyclobenzaprine) for PTSD Phase 3/RECOVERY • TNX - 10
Slide 60: Pipeline Summary – by Select Therapeutic Areas (continued)
© 2021 Tonix Pharmaceuticals Holding Corp. 60 Pipeline 1 Summary – by Select Therapeutic Areas (continued) Oncology • TNX - 1700 (rTFF2 2 ) for treatment of gastric and pancreatic cancer Preclinical Public Health • TNX - 1800 (live modified horsepox vaccine) for preventing COVID - 19 Preclinical • T
Slide 61: Financial Overview
© 2021 Tonix Pharmaceuticals Holding Corp. 61 Financial Overview NASDAQ: TNXP Cash and cash equivalents, December 31, 2020 Approximately $77 million Gross proceeds from registered direct equity offerings in 1Q2021 Approximately $110 million Shares outstanding as of March 15, 2021 Approximately 324 m
Slide 62: Milestones – Recently Completed and Upcoming
© 2021 Tonix Pharmaceuticals Holding Corp. 62 Milestones – Recently Completed and Upcoming 1 □ 4 th Quarter 2020 Non - human primate immune response positive results reported □ 4 th Quarter 2020 Positive topline data from TNX - 102 SL Phase 3 F304/RELIEF study in fibromyalgia reported □ 1 st Quarter
Slide 63: Management Team
© 2021 Tonix Pharmaceuticals Holding Corp. 63 Management Team Seth Lederman, MD President & CEO Jessica Morris Chief Operating Officer Gregory Sullivan, MD Chief Medical Officer Bradley Saenger , CPA Chief Financial Officer
Slide 64: Thank You!
© 2021 Tonix Pharmaceuticals Holding Corp. 64 Thank You!
Tonix Pharmaceuticals Holding — Investor Presentation (March 2021) on 6ix